<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="10" family="Giovanni-BookItalic,Italic" color="#000000"/>
	<fontspec id="font6" size="9" family="GillSans,BoldItalic" color="#000000"/>
	<fontspec id="font7" size="7" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font8" size="9" family="GillSans,Italic" color="#000000"/>
	<fontspec id="font9" size="10" family="Symbol" color="#000000"/>
<text top="41" left="55" width="162" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">Genetic Vaccines and Therapy 2007, 5 :5<i>Genetic Vaccines and Therapy</i></text>
<text top="41" left="394" width="160" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="1" tag_type="text">http://www.gvt-journal.com/content/5/1/5</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t3" reading_order_no="102" segment_no="20" tag_type="text">Page 2 of 9<b>5</b></text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t4" reading_order_no="103" segment_no="21" tag_type="text">(page number not for citation purposes)</text>
<text top="87" left="55" width="241" height="9" font="font4" id="p1_t5" reading_order_no="2" segment_no="2" tag_type="text">rate of 38% [11], placing these patients in danger of</text>
<text top="98" left="55" width="241" height="9" font="font4" id="p1_t6" reading_order_no="3" segment_no="2" tag_type="text">exhausting their treatment options [12]. Transmission of</text>
<text top="110" left="55" width="241" height="9" font="font4" id="p1_t7" reading_order_no="4" segment_no="2" tag_type="text">drug resistant HIV mutants is also an increasing problem.<i>(page number not for citation purposes)</i></text>
<text top="122" left="55" width="241" height="9" font="font4" id="p1_t8" reading_order_no="5" segment_no="2" tag_type="text">In a study among newly infected individuals, 14% of<a href=""> [11], plac</a>ing these patients in danger of</text>
<text top="134" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="6" segment_no="2" tag_type="text">patients were infected with HIV that already had one or<a href="">[12</a>]. Transmission of</text>
<text top="145" left="55" width="241" height="9" font="font4" id="p1_t10" reading_order_no="7" segment_no="2" tag_type="text">more key drug resistance mutations [13]. For these rea-</text>
<text top="157" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="8" segment_no="2" tag_type="text">sons, there is an increasing urgency to find a cure for HIV</text>
<text top="169" left="55" width="40" height="9" font="font4" id="p1_t12" reading_order_no="9" segment_no="2" tag_type="text">infection.</text>
<text top="192" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="10" segment_no="4" tag_type="text">With the advent of the molecular and genetic age of med-<a href="">13]. For th</a>ese rea-</text>
<text top="204" left="55" width="241" height="9" font="font4" id="p1_t14" reading_order_no="11" segment_no="4" tag_type="text">icine, research to create gene therapy for HIV has been on</text>
<text top="216" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="12" segment_no="4" tag_type="text">the rise. Since the 1980's, researchers have explored the</text>
<text top="228" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="13" segment_no="4" tag_type="text">possibility of using gene therapy to cure HIV-positive</text>
<text top="239" left="55" width="241" height="9" font="font4" id="p1_t17" reading_order_no="14" segment_no="4" tag_type="text">patients. In 1988, David Baltimore used the term 'intrac-</text>
<text top="251" left="55" width="241" height="9" font="font4" id="p1_t18" reading_order_no="15" segment_no="4" tag_type="text">ellular immunization' to describe this treatment approach</text>
<text top="263" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="16" segment_no="4" tag_type="text">[14]. Initial in vitro experiments were successful and now</text>
<text top="275" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="17" segment_no="4" tag_type="text">scientists are applying some of these methods in clinical</text>
<text top="286" left="55" width="23" height="9" font="font4" id="p1_t21" reading_order_no="18" segment_no="4" tag_type="text">trials.</text>
<text top="310" left="55" width="115" height="9" font="font6" id="p1_t22" reading_order_no="19" segment_no="7" tag_type="title">Strategies for inhibiting HIV<a href="">[14]. I</a>nitial </text>
<text top="322" left="55" width="241" height="9" font="font4" id="p1_t23" reading_order_no="20" segment_no="8" tag_type="text">Figure 1 is a schematic representation of the life cycle of<i>in vitro </i></text>
<text top="333" left="55" width="241" height="9" font="font4" id="p1_t24" reading_order_no="21" segment_no="8" tag_type="text">HIV showing the various stages at which genetic therapy</text>
<text top="345" left="55" width="241" height="9" font="font4" id="p1_t25" reading_order_no="22" segment_no="8" tag_type="text">could be applied. Therapy could also be aimed at any one</text>
<text top="357" left="55" width="241" height="9" font="font4" id="p1_t26" reading_order_no="23" segment_no="8" tag_type="text">of the many target cells for HIV infection in vivo , including</text>
<text top="368" left="55" width="241" height="10" font="font4" id="p1_t27" reading_order_no="24" segment_no="8" tag_type="text">immune cells such as CD4 + and CD8 + T cells, dendritic<i><b>Strategies for inhibiting HIV</b></i></text>
<text top="380" left="55" width="241" height="9" font="font4" id="p1_t28" reading_order_no="25" segment_no="8" tag_type="text">cells, monocytes, macrophages, hematopoietic stem cells<a href="">gure 1 is a </a>schematic representation of the life cycle of</text>
<text top="392" left="55" width="241" height="9" font="font4" id="p1_t29" reading_order_no="26" segment_no="8" tag_type="text">(HSCs), brain cells, and other cells from the gastrointesti-</text>
<text top="404" left="55" width="241" height="9" font="font4" id="p1_t30" reading_order_no="27" segment_no="8" tag_type="text">nal tracts that could serve as host cells for HIV. Since T</text>
<text top="416" left="55" width="241" height="9" font="font4" id="p1_t31" reading_order_no="28" segment_no="8" tag_type="text">cells are the major cell population implicated in HIV</text>
<text top="427" left="55" width="241" height="9" font="font4" id="p1_t32" reading_order_no="29" segment_no="8" tag_type="text">infection and its progression to AIDS, making these cells<i>in vivo</i></text>
<text top="439" left="55" width="241" height="9" font="font4" id="p1_t33" reading_order_no="30" segment_no="8" tag_type="text">immune to infection is a very important aspect of therapy.</text>
<text top="451" left="55" width="241" height="9" font="font4" id="p1_t34" reading_order_no="31" segment_no="8" tag_type="text">Even more desirable are the HSCs. These self-replicating</text>
<text top="463" left="55" width="241" height="9" font="font4" id="p1_t35" reading_order_no="32" segment_no="8" tag_type="text">progenitor cells give rise to all other members of the lym-</text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t36" reading_order_no="33" segment_no="8" tag_type="text">phoid and myeloid lineages and have the capability of</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t37" reading_order_no="34" segment_no="8" tag_type="text">repopulating the immune system with a potentially HIV-</text>
<text top="498" left="55" width="85" height="9" font="font4" id="p1_t38" reading_order_no="35" segment_no="8" tag_type="text">resistant phenotype.</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t39" reading_order_no="36" segment_no="11" tag_type="text">A variety of viral or cellular components could serve as tar-</text>
<text top="533" left="55" width="241" height="9" font="font4" id="p1_t40" reading_order_no="37" segment_no="11" tag_type="text">gets for anti-HIV gene therapy. Targeting viral factors is</text>
<text top="545" left="55" width="241" height="9" font="font4" id="p1_t41" reading_order_no="38" segment_no="11" tag_type="text">currently the most prevalent method. A major problem</text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t42" reading_order_no="39" segment_no="11" tag_type="text">with this strategy is that HIV can quickly form resistant</text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t43" reading_order_no="40" segment_no="11" tag_type="text">strains to these genetic modifications due to high muta-</text>
<text top="580" left="55" width="241" height="9" font="font4" id="p1_t44" reading_order_no="41" segment_no="11" tag_type="text">tion rates. Targeting cellular factors makes the occurrence</text>
<text top="592" left="55" width="241" height="9" font="font4" id="p1_t45" reading_order_no="42" segment_no="11" tag_type="text">of resistant strains less likely but raises the issues of</text>
<text top="604" left="55" width="241" height="9" font="font4" id="p1_t46" reading_order_no="43" segment_no="11" tag_type="text">adverse effects on normal cell function. HIV receptors and</text>
<text top="615" left="55" width="241" height="9" font="font4" id="p1_t47" reading_order_no="44" segment_no="11" tag_type="text">co-receptors are attractive targets, but there have been</text>
<text top="627" left="55" width="241" height="9" font="font4" id="p1_t48" reading_order_no="45" segment_no="11" tag_type="text">recent reports of liver toxicity with CCR5 antagonists in</text>
<text top="639" left="55" width="241" height="9" font="font4" id="p1_t49" reading_order_no="46" segment_no="11" tag_type="text">HIV-infected patients [15]. A summary of the main anti-</text>
<text top="651" left="55" width="125" height="9" font="font4" id="p1_t50" reading_order_no="47" segment_no="11" tag_type="text">viral approaches is as follows:</text>
<text top="674" left="55" width="100" height="9" font="font6" id="p1_t51" reading_order_no="48" segment_no="17" tag_type="title">Protein-based strategies</text>
<text top="686" left="55" width="110" height="9" font="font8" id="p1_t52" reading_order_no="49" segment_no="18" tag_type="title">A. Introduction of suicide genes</text>
<text top="698" left="55" width="241" height="9" font="font4" id="p1_t53" reading_order_no="50" segment_no="19" tag_type="text">Cells modified with suicide genes for negative selection.</text>
<text top="709" left="55" width="241" height="9" font="font4" id="p1_t54" reading_order_no="51" segment_no="19" tag_type="text">Generally, suicide genes code for enzymes that convert an</text>
<text top="721" left="55" width="241" height="9" font="font4" id="p1_t55" reading_order_no="52" segment_no="19" tag_type="text">inactive drug to a toxic form, allowing for the potential</text>
<text top="87" left="313" width="241" height="9" font="font4" id="p1_t56" reading_order_no="53" segment_no="3" tag_type="text">killing of the modified cells. The idea of using suicide</text>
<text top="98" left="313" width="241" height="9" font="font4" id="p1_t57" reading_order_no="54" segment_no="3" tag_type="text">genes was made popular as a potential approach for treat-</text>
<text top="110" left="313" width="241" height="9" font="font4" id="p1_t58" reading_order_no="55" segment_no="3" tag_type="text">ing cancer. As an anti-HIV strategy this method was tried</text>
<text top="122" left="313" width="241" height="9" font="font5" id="p1_t59" reading_order_no="56" segment_no="3" tag_type="text">in vitro as proof-of-concept in a study that used a retrovi-</text>
<text top="134" left="313" width="241" height="9" font="font4" id="p1_t60" reading_order_no="57" segment_no="3" tag_type="text">rus to transduce autologous CD8+ cells from HIV-infected<a href="">15</a>]. A summary of the main anti-</text>
<text top="145" left="313" width="241" height="9" font="font4" id="p1_t61" reading_order_no="58" segment_no="3" tag_type="text">patients; the suicide gene was thymidine kinase expressed</text>
<text top="157" left="313" width="241" height="9" font="font4" id="p1_t62" reading_order_no="59" segment_no="3" tag_type="text">as a fusion protein with hygromycin phosphotransferase<i><b>Protein-based strategies</b></i></text>
<text top="169" left="313" width="241" height="9" font="font4" id="p1_t63" reading_order_no="60" segment_no="3" tag_type="text">[16]. As with other gene therapy approaches, specific tar-<i>A. Introduction of suicide genes</i></text>
<text top="181" left="313" width="241" height="9" font="font4" id="p1_t64" reading_order_no="61" segment_no="3" tag_type="text">geting of desired HIV-infected cell populations would</text>
<text top="192" left="313" width="241" height="9" font="font4" id="p1_t65" reading_order_no="62" segment_no="3" tag_type="text">present a challenge for this approach to be successful in</text>
<text top="204" left="313" width="18" height="9" font="font5" id="p1_t66" reading_order_no="63" segment_no="3" tag_type="text">vivo .</text>
<text top="228" left="313" width="126" height="9" font="font8" id="p1_t67" reading_order_no="64" segment_no="5" tag_type="title">B. Transdominant negative proteins</text>
<text top="239" left="313" width="241" height="9" font="font4" id="p1_t68" reading_order_no="65" segment_no="6" tag_type="text">Mutations in a specific gene expressed in a dominant fash-</text>
<text top="251" left="313" width="241" height="9" font="font4" id="p1_t69" reading_order_no="66" segment_no="6" tag_type="text">ion where the mutant protein can interfere with the func-</text>
<text top="263" left="313" width="241" height="9" font="font4" id="p1_t70" reading_order_no="67" segment_no="6" tag_type="text">tion normally carried out by the parent gene product. If<i>in vitro </i></text>
<text top="275" left="313" width="241" height="9" font="font4" id="p1_t71" reading_order_no="68" segment_no="6" tag_type="text">the protein is multimeric, the nonfunctional protein can</text>
<text top="286" left="313" width="241" height="9" font="font4" id="p1_t72" reading_order_no="69" segment_no="6" tag_type="text">multimerize with the normal protein and the resultant</text>
<text top="298" left="313" width="241" height="9" font="font4" id="p1_t73" reading_order_no="70" segment_no="6" tag_type="text">complex is functionally inactive. Thus, the dominant neg-</text>
<text top="310" left="313" width="241" height="9" font="font4" id="p1_t74" reading_order_no="71" segment_no="6" tag_type="text">ative protein can have a strong inhibitory effect on the</text>
<text top="322" left="313" width="241" height="9" font="font4" id="p1_t75" reading_order_no="72" segment_no="6" tag_type="text">normal protein formation or function. Examples of this<a href="">[16</a>]. As with other gene therapy approaches, specific tar-</text>
<text top="333" left="313" width="241" height="9" font="font4" id="p1_t76" reading_order_no="73" segment_no="6" tag_type="text">are HIV-1 Gag mutants [17] and Rev M10 [18]. Rev M10</text>
<text top="345" left="313" width="241" height="9" font="font4" id="p1_t77" reading_order_no="74" segment_no="6" tag_type="text">was the first transdominant negative protein used in clin-</text>
<text top="357" left="313" width="241" height="9" font="font4" id="p1_t78" reading_order_no="75" segment_no="6" tag_type="text">ical trials; it is a dominant negative mutant capable of<i>in</i></text>
<text top="369" left="313" width="241" height="9" font="font4" id="p1_t79" reading_order_no="76" segment_no="6" tag_type="text">binding the Rev Responsive Element (RRE) and has the<i>vivo</i></text>
<text top="380" left="313" width="158" height="9" font="font4" id="p1_t80" reading_order_no="77" segment_no="6" tag_type="text">capability of forming multimers [18].</text>
<text top="404" left="313" width="76" height="9" font="font8" id="p1_t81" reading_order_no="78" segment_no="9" tag_type="title">C. Chimeric receptors<i>B. Transdominant negative proteins</i></text>
<text top="413" left="313" width="241" height="13" font="font4" id="p1_t82" reading_order_no="79" segment_no="10" tag_type="text">CD4/CD3 chimeric receptor called CD4 ζ . The CD4 ζ has</text>
<text top="427" left="313" width="241" height="9" font="font4" id="p1_t83" reading_order_no="80" segment_no="10" tag_type="text">the extracellular and transmembrane domains of the CD4</text>
<text top="439" left="313" width="241" height="9" font="font4" id="p1_t84" reading_order_no="81" segment_no="10" tag_type="text">antigen and the intracytoplasmic domain of the CD3 T</text>
<text top="451" left="313" width="241" height="9" font="font4" id="p1_t85" reading_order_no="82" segment_no="10" tag_type="text">cell receptor. The extracellular portion binds HIV, while</text>
<text top="463" left="313" width="241" height="9" font="font4" id="p1_t86" reading_order_no="83" segment_no="10" tag_type="text">the cytoplasmic portion initiates a signaling cascade simi-</text>
<text top="474" left="313" width="241" height="9" font="font4" id="p1_t87" reading_order_no="84" segment_no="10" tag_type="text">lar to the one initiated by the normal T-cell receptor (TCR)</text>
<text top="484" left="313" width="241" height="13" font="font4" id="p1_t88" reading_order_no="85" segment_no="10" tag_type="text">binding with HIV [19]. Thus, engagement of CD4 ζ with</text>
<text top="498" left="313" width="241" height="9" font="font4" id="p1_t89" reading_order_no="86" segment_no="10" tag_type="text">HIV results in the generation of an HIV-specific T cell</text>
<text top="507" left="313" width="241" height="13" font="font4" id="p1_t90" reading_order_no="87" segment_no="10" tag_type="text">response. CD4 ζ -modified T lymphocytes inhibit viral rep-<a href="">[17] and Rev M10 [18]</a>. Rev M10</text>
<text top="521" left="313" width="241" height="9" font="font4" id="p1_t91" reading_order_no="88" segment_no="10" tag_type="text">lication in T cells and macrophages in vitro [20] and medi-</text>
<text top="533" left="313" width="160" height="9" font="font4" id="p1_t92" reading_order_no="89" segment_no="10" tag_type="text">ate killing of HIV-infected T cells [19].</text>
<text top="557" left="313" width="207" height="9" font="font8" id="p1_t93" reading_order_no="90" segment_no="12" tag_type="title">D. Intracellular HIV-1 specific single chain antibodies (SFv)</text>
<text top="568" left="313" width="241" height="9" font="font4" id="p1_t94" reading_order_no="91" segment_no="13" tag_type="text">These antibodies bind to viral proteins intracellularly and<a href="">ers [18]</a>.</text>
<text top="580" left="313" width="241" height="9" font="font4" id="p1_t95" reading_order_no="92" segment_no="13" tag_type="text">block their action, e.g. anti-Rev SFv [21] and anti-gp120<i>C. Chimeric receptors</i></text>
<text top="592" left="313" width="37" height="9" font="font4" id="p1_t96" reading_order_no="93" segment_no="13" tag_type="text">SFv [22].</text>
<text top="616" left="313" width="89" height="9" font="font6" id="p1_t97" reading_order_no="94" segment_no="14" tag_type="title">RNA-based strategies</text>
<text top="627" left="313" width="52" height="9" font="font8" id="p1_t98" reading_order_no="95" segment_no="15" tag_type="title">A. RNA decoys</text>
<text top="639" left="313" width="241" height="9" font="font4" id="p1_t99" reading_order_no="96" segment_no="16" tag_type="text">Small RNA molecules containing essential cis -acting ele-</text>
<text top="651" left="313" width="242" height="9" font="font4" id="p1_t100" reading_order_no="97" segment_no="16" tag_type="text">ments that bind trans -acting proteins. They function by</text>
<text top="662" left="313" width="241" height="9" font="font4" id="p1_t101" reading_order_no="98" segment_no="16" tag_type="text">luring away trans -acting proteins from their true target</text>
<text top="674" left="313" width="241" height="9" font="font4" id="p1_t102" reading_order_no="99" segment_no="16" tag_type="text">sequence. When expressed at high levels, they can success-</text>
<text top="686" left="313" width="241" height="9" font="font4" id="p1_t103" reading_order_no="100" segment_no="16" tag_type="text">fully compete against viral cis -acting sequences that are</text>
<text top="698" left="313" width="178" height="9" font="font4" id="p1_t104" reading_order_no="101" segment_no="16" tag_type="text">indispensable for viral replication [23,24].</text>
</page>
</pdf2xml>
